C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
Status:
Completed
Trial end date:
2017-03-13
Target enrollment:
Participant gender:
Summary
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high
risk for delayed graft function (DGF) may show significant improvement in outcomes post
transplant compared with patients that do not receive C1INH treatment. Complement activation
has been detected in animal models and human kidneys with ischemic reperfusion injury (IRI)
and inflammatory cell infiltrates. By blocking complement activation the investigators hope
to improve kidney graft function post transplant in these recipients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein Complement C1s